Medtronic is a global leader in medical technology, focused on developing and providing innovative therapeutic solutions to improve the lives of patients. The company specializes in a wide range of medical devices and therapies, addressing conditions in areas such as diabetes care, cardiovascular health, surgical innovations, and neurological disorders. Medtronic is committed to advancing healthcare through cutting-edge research, collaboration with healthcare providers, and a strong emphasis on patient-centered care, aiming to enhance the quality of life for millions around the world. Read More
As the S&P 500 navigates a dynamic market on October 3, 2025, the Healthcare sector has emerged as a steadfast performer, demonstrating remarkable resilience and contributing significantly to the overall market's strength. This stability comes at a crucial time, as the technology sector experiences a notable pullback, leading investors
Merit Medical Systems (NASDAQ: MMSI) has announced a significant milestone for its SCOUT Radar Localization technology, which has now been utilized in over 750,000 patient procedures worldwide. This achievement, coinciding with Breast Cancer Awareness Month, underscores the widespread adoption and critical impact of the wire-free, non-radioactive localization device in
The financial markets are buzzing with the significant upward trajectory of several big tech and tech-adjacent companies, with prominent players like Palo Alto Networks, Intel, Travelers, and Medtronic reportedly reaching new valuation highs. This surge, observed around October 2025, signals a robust investor confidence in the technology sector's resilience and
On October 2, 2025, the Healthcare sector emerged as a beacon of stability and growth within the S&P 500, delivering a robust positive performance that significantly contributed to the broader market's resilience. Despite prevailing anxieties, including a looming U.S. government shutdown and a disappointing jobs report, healthcare equities
Silicon Valley, CA - October 2, 2025 - Entrepreneur, investor, and author Pedro David Espinoza has announced the release of the audiobook edition of his acclaimed book “ The Real ROI: Return on Inclusion .” The audiobook explores how inclusive leadership fuels innovation, growth, and profitability, drawing on lessons and insights from some of the world’s most influential business leaders.
As of October 1, 2025, Artificial Intelligence (AI) has transcended its nascent stages, becoming an indispensable force in high-value professional tasks across medicine, law, and consulting. This transformative shift is redefining traditional workflows, demanding a radical re-evaluation of skill sets, and igniting critical discussions around ethics, regulation, and the very
As of late September 2025, the specter of a US government shutdown casts a long shadow over financial markets, prompting an immediate atmosphere of caution and uncertainty. With the fiscal year-end deadline of September 30 rapidly approaching, stock futures, the S&P 500, Dow, and Nasdaq are all feeling the
(NewsUSA) - Do you ever notice a flutter in your chest? Feel unusually tired even after a good night’s sleep? Get winded from walking up the stairs when that never used to happen? These little signs might not feel like a big deal, but they could point to something more serious: atrial fibrillation, or AFib.
The U.S. Commerce Department, under the Trump administration, has launched a national security review of medical imports—including PPE, consumables, and medical devices—to assess reliance on foreign suppliers for critical health products.
The pharmaceutical landscape is currently a tale of two giants employing vastly different, yet highly successful, growth strategies. Eli Lilly and Company (NYSE: LLY) has placed an extraordinary bet on the burgeoning market for weight-loss and diabetes drugs, driven by its groundbreaking GLP-1 agonists. In stark contrast, Johnson & Johnson (NYSE:
Johnson & Johnson (NYSE: JNJ), the global healthcare titan, has once again underscored its formidable market position and unwavering commitment to shareholder value, reporting a robust second quarter for 2025. The company's performance was marked by significant growth across its Innovative Medicine and MedTech segments, showcasing the strategic success of its
Medtronic's Altaviva wins FDA approval as a minimally invasive implant for urge urinary incontinence, offering long-lasting and low-maintenance therapy.
In a financial landscape increasingly dominated by the exhilarating, often volatile, narrative of artificial intelligence, Intuitive Surgical (NASDAQ: ISRG) stands as a testament to steady, fundamental innovation. As the market's gaze fixates on every whisper of AI advancement, the pioneer of robotic-assisted surgery continues its work, quietly refining its formidable
Sunnyvale, CA – September 17, 2025 – Intuitive Surgical (NASDAQ: ISRG), the pioneer and global leader in robotic-assisted surgery, has once again demonstrated its formidable market position with a robust second-quarter 2025 earnings report. The company announced an impressive adjusted Earnings Per Share (EPS) of $2.19, significantly surpassing analyst expectations, coupled
Medtronic (MDT) offers a strong 3.01% dividend yield, a history of reliable payouts, and solid profitability, making it a top candidate for sustainable income investors.
